Selpercatinib showed a statistically significant improvement in event-free survival (EFS) as adjuvant therapy in patients with early-stage RET fusion-positive NSCLC. Overall survival trended positively (data immature), and safety was consistent with prior trials.

Detailed results will be shared at an upcoming medical meeting.

These results also reinforce the importance of genomic testing at diagnosis. Identifying RET fusions helps ensure patients can access personalized treatments designed for their cancer. Advances like this bring hope and move us closer to better outcomes for people living with early stage RET-positive lung cancer.

Read more: https://investor.lilly.com/news-releases/news-release-details/lillys-retevmo-selpercatinib-delivers-substantial-event-free

LIBRETTO-432 clinical trial: https://clinicaltrials.gov/study/NCT04819100

If you or your loved one has been diagnosed with RET-positive lung cancer, it is especially important to find a thoracic oncologist (a lung cancer specialist) who is familiar with the latest research and treatment options for RET-driven cancers. Because RET-positive lung cancer is relatively rare, having an oncologist with specific expertise in this area can make a significant difference in accessing the most effective therapies, including targeted treatments and clinical trials.

Your oncologist will become your partner throughout this journey, helping you understand your diagnosis, reviewing treatment choices, monitoring progress, and adjusting your care as needed. A good oncologist will also collaborate closely with other specialists, such as radiologists, pathologists, and genetic counselors, to ensure your care is personalized and coordinated.

When searching for the right oncologist, here are a few helpful steps to consider:

• Ask your diagnosing doctor for a referral
  The doctor who identified your cancer (such as a pulmonologist or pathologist) can often recommend an oncologist with experience treating lung cancers that involve RET fusions or mutations.
• Explore NCI-Designated Cancer Centers
  The National Cancer Institute (NCI) recognizes leading cancer centers across the United States that deliver cutting-edge treatments and conduct advanced research. Choosing an oncologist affiliated with one of these centers may give you access to the newest RET-targeted therapies and clinical trials. You can find the full list of NCI-designated centers on the National Cancer Institute website.
• Consult your primary care provider
  Your primary care doctor can also help coordinate referrals and assist with scheduling appointments at specialized cancer centers.
• Consider clinical trial sites
  Some major cancer centers are actively enrolling patients in RET-specific clinical trials, which can provide access to promising new treatments not yet widely available.

Below are some oncologists recognized for their work and expertise in RET-positive lung cancer research and treatment:

Dr. John V. Heymach – Professor and Chair Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center (USA)
Dr. Heymach leads pioneering research on mechanisms of sensitivity and resistance to RET inhibitors, helping guide personalized treatment strategies for RET-positive lung cancer. His research has led to new therapeutic approaches for oncogene-driven lung cancer types, many of which are now considered standard of care regimens or undergoing clinical testing. Contact Dr. John Heymach

More info here

Dr. Alex Drilon – Associate Director, Early Drug Development, Memorial Sloan Kettering Cancer Center (USA)
A leading clinical researcher in targeted therapies, Dr. Drilon led the pivotal trials that established selective RET inhibitors as a standard of care, significantly improving outcomes for patients with RET-positive lung cancer. Contact Dr. Alex Drilon

More info here

Dr. Marc Ladanyi – Molecular Pathologist, Memorial Sloan Kettering Cancer Center (USA)
Dr. Ladanyi has made major contributions to understanding the genomic landscape of lung cancer, including identifying and characterizing mechanisms of resistance in oncogene-driven cancers such as RET-positive lung cancer. Contact Dr. Marc Ladanyi

More info here

Dr. Justin Gainor – Director, Center for Thoracic Cancers, Massachusetts General Hospital (USA)
Dr. Gainor focuses on translational research in oncogene-driven lung cancers. His work explores resistance mechanisms and the development of next-generation targeted therapies for RET-positive lung cancer and other oncogene-driven cancers. Contact Dr. Justin Gainor

More info here

Dr. Jessica Lin – Medical Oncologist, Massachusetts General Hospital (USA)
Dr. Lin specializes in clinical and translational research in RET-positive and other oncogene-driven lung cancers, contributing to studies that shape treatment sequencing and resistance management. She is the leader of the RETgistry, a global consortium of patients with advanced RET-altered solid tumors who received SRIs. Contact Dr. Jessica Lin

More info here

Dr. David Carbone – Director, The James Thoracic Oncology Center (USA)
A leader in precision oncology, Dr. Carbone integrates genomic testing into lung cancer care, ensuring patients with rare alterations such as RET receive tailored treatment options and access to clinical trials. Contact Dr. David Carbone

More info here

Dr. Vivek Subbiah – Director, Precision Oncology, Sarah Cannon Research Institute (USA)
Dr. Subbiah is recognized for his work in precision oncology and has led multiple early-phase clinical trials exploring targeted therapies for RET-altered cancers and other rare genetic drivers. Contact Dr. Vivek Subbiah

Dr. Tejas Patil – Medical Oncologist, UCHealth Lung Cancer Clinic – Anschutz Medical Campus (USA)
Dr. Patil is a clinical expert and researcher focused on RET-positive lung cancer. He is actively involved in managing acquired resistance to targeted therapies such as RET inhibitors and developing rational therapy combinations based on molecular and evolutionary biology. Contact Dr. Tejas Patil

Dr. Mihaela Aldea – Medical Oncologist, Gustave Roussy (France)
Dr. Aldea leads international collaborations on RET-positive lung cancer, including the RET-MAP registry, which collects real-world data across Europe to improve understanding of resistance and treatment outcomes. Contact Dr. Mihaela Alea

More info here

Dr. Yasir Elamin- Associate Professor, Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center (USA).

Dr. Elamin is a dedicated thoracic oncologist who leads several clinical studies for oncogene-driven lung cancers. He was co-chair on one clinical study Lung-MAP testing selpercatinib with chemotherapy. Contact Dr. Yasir Elamin

Dr. Julia Rotow – Physician-Scientist, Dana-Farber Cancer Institute (USA)
Dr. Rotow specializes in the development of targeted therapies and immunotherapies for oncogene-driven lung cancers. She is actively involved in clinical trials and collaborative research efforts. Contact Dr. Julia Rotow

More info here

These specialists have contributed to RET research, clinical trials, and the development of targeted therapies.

Important Note: This is not a complete list of experts. There are many experienced thoracic oncologists across the United States and internationally who treat patients with RET-positive lung cancer.

If you are considering consulting with a RET expert:

• Ask whether they have experience treating RET-positive patients
• Inquire about clinical trial opportunities for RET cancer
• Discuss how care can be coordinated with your local oncology team

In the 4th Annual End-of-Year RET Research Webinar, industry partners and leading researchers shared the latest insights into RET biology, treatment resistance, and emerging strategies aimed at improving outcomes for patients with RET-driven cancers.

We are deeply grateful to all of the presenters for sharing their insightful and compelling perspectives on RET-positive cancer research and future directions. We also thank our sponsors – Lilly, Ellipses, and Rigel – and the nearly 130 participants and members of the broader RET lung cancer community who joined us for the 2025 RET Research Update.

Your continued support of The Happy Lungs Project is helping drive meaningful research progress. We invite you to watch the webinar recording and read the recap below.

Research Presentations:

Rigel Pharmaceuticals:

Dr. Cynthia Villarimo from Rigel Pharmaceuticals, shared updates on Rigel’s RET research pipeline, highlighting pralsetinib (Gavreto) and ongoing efforts to improve outcomes for patients with RET fusion–positive cancers. Rigel is a fully integrated biopharmaceutical company with three FDA-approved therapies across hematology and oncology, including Gavreto, for RET fusion–positive metastatic non-small cell lung cancer (NSCLC) and RET positive thyroid cancer. Approval of pralsetinib was supported by results from the ARROW trial, which demonstrated durable responses across RET-positive solid tumors.

Dr. Villarimo shared Rigel’s ongoing research that focuses on overcoming resistance through combination strategies, evaluating intracranial efficacy, and exploring RET fusions in additional tumor types, including pancreatic and colorectal cancers. Dr. Villarimo also highlighted challenges in biomarker testing, including long turnaround times of 2 or 3 weeks. These delays may contribute to some patients receiving chemotherapy instead of targeted therapy.

To support timely access, Rigel offers patient assistance programs, copay support, and free drug supply coordination. More information is available at RigelOneCare.com.

Ellipses Pharma:

On behalf of Ellipses Pharma, Dr. Alex Drilon, Medical Oncologist at Memorial Sloan Kettering Cancer Center, presented an overview of the evolving treatment landscape for RET fusion–driven cancers, with a focus on lunbotinib (EP0031), a next-generation RET inhibitor currently in global clinical development by Ellipses Pharma.

For patients with RET fusion–positive NSCLC, first-line treatment typically involves selective RET inhibitors such as pralsetinib or selpercatinib, which provide durable benefit for many patients. However, once resistance develops, treatment options are limited and often shift to non-targeted chemotherapy. This unmet need has driven the development of newer RET inhibitors designed to extend benefit and overcome resistance.

Dr. Drilon emphasized that not all investigational RET inhibitors are truly next generation. Key differentiators include the activity against RET resistance mutations, particularly the RET G810, improved brain penetration, and clinical activity in patients previously treated with selective RET inhibitors

Dr. Drilon mentioned that while many RET inhibitors are in development globally, particularly in Asia, few demonstrate these features. Lunbotinib is currently the only next-generation RET inhibitor in active clinical development across Asia, Europe, and the United States, with more than 500 patients treated worldwide. Early-phase studies have shown:

• Meaningful tumor responses in RET fusion–positive lung and thyroid cancers
• Activity in the brain, an important consideration for RET-driven NSCLC
• Clinical responses in patients who previously progressed on pralsetinib or selpercatinib
• Activity against the challenging RET G810 resistance mutation

The objective response rates exceeded 40%, with disease control observed in over 80% of patients, and side effects were generally mild to moderate.

Beyond monotherapy, Dr. Drillon mentioned that lunbotinib is now being studied in combination with chemotherapy, both in patients new to RET inhibitors and in those previously treated. This approach is supported by the lessons learned from EGFR-positive lung cancer, where combining EGFR targeted therapy (osimertinib) with chemotherapy improves outcomes compared with targeted therapy alone.

Lilly:

Dr. Aimee Lin and Dr. Jennifer Wright from Lilly shared updates on the RET inhibitor selpercatinib, focusing on a major formulation change designed to improve patient experience. While selpercatinib continues to show strong clinical benefit across RET-driven cancers, Lilly recently transitioned the drug from capsules to smaller, easier-to-swallow tablets.

Approved by the FDA in April 2024, the tablet formulation offers fewer pills per dose, more flexible dosing, and improved usability, which is especially important for pediatric patients. Feedback from patients notes that the change makes daily treatment feel “less of a thing,” underscoring Lilly’s commitment to patient-centered innovation.

Troper Wojcicki Philanthropies:

Dr. Caitlin Nichols of Troper Wojcicki Philanthropies shared an update on the Lung Cancer Genetics Study, a national research effort created in partnership with 23andMe Research Institute and more than 20 lung cancer advocacy organizations, including The Happy Lungs Project.

The study’s goal is to better understand how genetics, environment, and lifestyle factors influence lung cancer risk, early detection, and treatment. Participants provide a saliva sample for genetic analysis and complete surveys about diagnosis, biomarker testing, treatments, exposures, and family history. De-identified data are securely shared with qualified researchers, with patients involved in reviewing research proposals to ensure studies reflect community priorities.

Dr. Nichols shared that 23andMe has transitioned to the 23andMe Research Institute, a nonprofit organization dedicated to advancing medical research.

The study is open to any U.S. adult who has ever been diagnosed with lung cancer, at no cost to participants. More than 1,300 people have already enrolled, with a goal of reaching 10,000 participants. Early data show strong representation of women and younger patients. Sixteen patients with RET lung cancer have joined the study, and about 400 participants reported they had a tumor biomarker.

Dr. Nichols noted that by growing this study, researchers hope to identify genetic risk factors, improve screening strategies, and ultimately support the development of more personalized treatments. Community participation and advocacy partnerships remain central to the study’s success. Those interested in learning more or enrolling can visit 23andMe.com/lung-cancer.

Dr. John Heymach, MD Anderson Cancer Center:

Dr. John Heymach, Professor and Chair of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, shared new research advances from his team that were made possible through funding from The Happy Lungs Project.

A central focus of Dr. Heymach’s work is the idea that not all RET fusions are the same. While RET-positive lung cancers are often treated as a single group, Dr. Heymach’s team showed that different RET fusions, such as KIF5B and CCDC6, can behave differently and respond differently to treatment. Using RET cell lines engineered in the lab to carry different RET fusions and mutations, the researchers found meaningful differences in drug sensitivity, even among patients treated with the same RET inhibitors.

These laboratory findings are supported by clinical data. Patients with CCDC6-RET fusions showed longer progression-free survival and overall survival compared with those with KIF5B-RET fusions. This suggests that fusion type may influence outcomes and could eventually help guide treatment decisions.

The team is also uncovering important differences in how RET fusions arise in different settings. For example, KIF5B-RET fusions are more common at initial diagnosis, while CCDC6-RET and other fusions are more often seen as resistance mechanisms in patients with EGFR-mutant lung cancer, pointing to distinct biological contexts.

Another major focus of the research is RET drug resistance. Using an innovative approach called Lentimutate developed by Dr. Ralf Kittler (UT Southwestern), the team can rapidly generate and study all possible resistance mutations in RET, rather than waiting for them to emerge in patients. This has revealed that resistance patterns differ not only by drug (such as selpercatinib vs. pralsetinib), but also by fusion partner. This knowledge has already helped guide switching between RET inhibitors when resistance develops.

Beyond mutations in RET itself, the researchers are exploring alternative resistance pathways, including signaling through EGFR, HER3, and MET. Preclinical studies suggest that combining RET inhibitors with newer therapies, such as EGFR/HER3–targeted antibody-drug conjugates, may help overcome resistance.

Looking ahead, Dr. Heymach’s team is identifying new cell-surface targets that appear in drug-resistant or drug-tolerant cancer cells. These discoveries are already being used to develop experimental CAR-T therapies and T-cell engagers, offering potential new strategies for patients whose cancers no longer respond to current RET inhibitors. The group is also exploring AI-driven “digital twin” models to better predict treatment response and accelerate clinical research.

During the Q&A, Dr. Heymach further explained how researchers are using a new tool called “digital twins” to help test new cancer treatments faster and more accurately. Traditional clinical trials, especially large randomized trials, are very expensive and can take many years to complete. Because of this, companies are sometimes hesitant to run them. A digital twin is a computer-generated model of a patient, which is created using large amounts of real patient data. It includes information such as tumor size and how the cancer typically changes over time. Researchers use artificial intelligence to predict how a patient would be expected to do on today’s standard treatment. The goal of this approach is to speed up drug development, identify promising treatments sooner, and help bring effective new therapies to patients more quickly.

Dr. Mihaela Aldea, Institut Gustave Roussy:

Dr. Mihaela Aldea, Medical Oncologist at Institut Gustave Roussy, presented emerging research focused on treatment strategies after progression on selective RET inhibitors in RET fusion–positive NSCLC. Her work builds on a global RET registry launched in 2021 (RET-MAP), which now includes data from more than 500 patients across 48 centers worldwide, enabling detailed study of resistance and new therapeutic opportunities.

Dr. Aldea pointed out that while selective RET inhibitors have transformed care for patients with RET fusions, progression eventually occurs for many patients. At that point, treatment options are limited, as RET-positive tumors tend to respond poorly to immunotherapy, highlighting the need for new targeted approaches.

Dr. Aldea’s research focuses on identifying cell-surface targets that could be exploited by antibody drug conjugates (ADCs) or bispecific antibodies. By analyzing tumor samples from 93 RET-positive patients across 12 European institutions her team evaluated expression of targets including MET, HER2, EGFR, HER3, and TROP2 using immunohistochemistry and gene-expression profiling.

The findings revealed that TROP2 is commonly expressed in RET-positive lung cancers, consistent with other lung adenocarcinomas. More notably, MET expression was significantly higher in RET-positive tumors compared with RET-negative ones, and MET levels often increased after progression on RET inhibitors. Importantly, multiple targets were frequently co-expressed, suggesting that dual-target or bispecific therapies may be effective.

Another key discovery involved angiogenesis, the process by which tumors form new blood vessels. RET-positive tumors showed a stronger angiogenic gene-expression signature and this signature appeared to be further enriched after resistance to RET inhibitors. Laboratory models confirmed that resistant cancer cells could form vessel-like networks, a phenomenon known as vasculogenic mimicry.

Building on these findings, Dr. Aldea’s team tested bevacizumab, an anti-angiogenic drug, in combination with chemotherapy in preclinical models. The combination disrupted vessel-like structures, reduced tumor cell migration, and increased cancer cell death. Retrospective clinical data also suggested a signal of benefit for bevacizumab plus chemotherapy, including in first line treatment, although patient numbers were small, and results require confirmation in prospective studies.

Dr. Aldea concluded that MET and TROP2 are promising targets for future ADC development in RET-positive lung cancer, particularly at progression. Anti-angiogenic strategies, either with bevacizumab or newer VEGF and immune-targeting combinations, may offer additional options, especially in regions where selective RET inhibitors are not yet widely available. She pointed out that further prospective trials will be essential to determine how best to integrate these approaches into clinical care.

Dr. David Carbone, The Ohio State University Cancer Center:

Dr. David Carbone, Professor and Director of the James Oncology Center at The Ohio State University, discussed strategies to improve outcomes for patients with RET fusion positive lung cancer beyond current RET targeted therapies. While selective RET inhibitors have significantly advanced care, Dr. Carbone emphasized that drug resistance remains inevitable, highlighting the need for complementary approaches.

Dr. Carbone shared the  plans for the creation of a multi-institution RET research consortium, coordinated through MD Anderson, to accelerate progress through shared resources, patient samples, and collaborative projects. This model would allow researchers to test new strategies, such as locally ablative therapies, antibody-drug conjugates (ADCs), and bispecific antibodies, more efficiently across institutions.

Dr. Carbone also outlined ongoing research aimed at identifying novel cell-surface protein targets specific to RET-driven tumors and to drug-tolerant “persister” cells that survive after initial treatment. Using advanced cell-surface proteomic techniques, his team has already identified promising new targets in other fusion-driven cancers (ALK), with plans to extend this work to RET fusions.

Together, these efforts aim to move beyond incremental improvements in TKIs and toward next-generation therapies that could delay resistance, improve durability of response, and ultimately enhance long-term outcomes for patients with RET-positive lung cancer.

By Anthony Sireci, M.D., senior vice president of clinical biomarkers, laboratories and diagnostics at Eli Lilly and Company

Often, when people hear “biomarker testing” in relation to lung cancer, they associate it with advanced-stage disease. However, the treatment paradigm for non-small cell lung cancer (NSCLC) has evolved significantly in recent years and we see more therapies being introduced in the earliest stages of cancer, including in the neoadjuvant setting. Similar to how we think about biomarker testing in the advanced stages, comprehensive genomic profiling (CGP) is proving to be just as critical in early-stage NSCLC.

CGP is a thorough type of biomarker testing that looks for alterations in the DNA and sometimes RNA of a patient’s tumor cells in a single test to better understand the genomic drivers of their cancer. CGP in early-stage NSCLC can help inform targeted treatment options for patients in whom a potentially actionable genomic target is detected, similar to how it is used in later stage cancer, allowing for a better understanding of one’s cancer and an opportunity to receive care that is tailored to an individual’s unique cancer profile earlier in the treatment journey. 

Why Testing in Early-Stage Matters

For patients with early-stage NSCLC, surgery is typically the first step in treatment. But as the treatment landscape continues to shift, people with NSCLC are no longer limited to surgery. Increasingly, alternative options are being used before surgery (neoadjuvant) or after surgery (adjuvant), and healthcare professionals can use CGP results to help guide treatment decisions with their patients as more targeted therapies become available in these early settings. 

As the number of lung cancer diagnoses increasingly occur at earlier stages, the role of CGP continues to grow. Early genomic testing is important as the genomic drivers of the disease remain consistent from diagnosis throughout the course of their disease, so CGP results are available to inform every therapy decision, including if a patient progresses to metastatic disease. Early stage CGP can also rule out immunotherapy in certain biomarker-positive patients. Delaying testing can result in losing valuable time on ineffective treatments and interventions, and when it comes to cancer care, time is always of the essence.

What Patients Can Expect from CGP

Once someone is diagnosed with lung cancer, the next essential step is a conversation between the patient and their care team about available treatment options, and this conversation should include plans for CGP. 

Here’s what someone might expect from CGP testing, at a high-level: 

• Often, the tumor sample, or biopsy, that was collected from a patient for diagnosis, can be used for CGP 
• The biopsy sample is sent to a specialized lab
• DNA and/or RNA is extracted from the sample
• The genetic material is sequenced to identify potentially actionable mutations or alterations
• A detailed report is generated and shared with the treating physician to help guide treatment decisions

The Impact of CGP on Treatment Options

Targeted therapies have become increasingly available for early-stage lung cancer, thanks to years of research and innovation. However, these treatments are only a viable option if a patient’s biomarkers are identified. For example, certain genomic alterations may qualify a patient for a specific therapy after surgery, or for a pre-surgical treatment that can shrink the tumor and improve surgical outcomes.

Just a decade ago, targeted therapies for early-stage NSCLC were nonexistent. Today, we’re seeing a rapid shift toward earlier diagnosis and intervention, with more therapies being approved or studied for use in early-stage patients. Over the next few years, this trend will likely only accelerate, making CGP at diagnosis a vital first step in ensuring patients have access to the most effective treatment options available at diagnosis.

Encouraging Uptake and Awareness

Patients and care teams both play a role in making early CGP routine practice. To ensure biomarker testing becomes a standard part of lung cancer care, several elements must work together: streamlined workflows that integrate testing into the diagnosis process, education for both patients and healthcare providers, and open communication between the two to keep testing front of mind. 

For patients, a cancer diagnosis can be overwhelming. Amid the whirlwind of emotions, it’s important to remain focused on treatment and feeling empowered to ask a healthcare provider about CGP. Once results are available, understanding how they inform treatment plans can help patients take an active role in their care.

For care teams, staying abreast of the latest advancements in biomarker testing and maintaining efficient workflows are essential. Providers play a key role in making CGP a routine part of the diagnostic process, ensuring results are available as early as possible to guide treatment decisions.

CGP isn’t just for advanced NSCLC, it’s for all stages of lung cancer. The earlier it’s done, the more time patients and HCPs have to understand which options could be most effective. 

Guest Author Bio:

Anthony “Nino” Sireci, MD is the senior vice president of clinical biomarkers, laboratories and diagnostics at Eli Lilly and Company.  

Dr. Sireci is a board-certified Clinical Pathologist and a practicing molecular pathologist. Prior to joining Lilly, he was an Assistant Professor of Pathology and Cell Biology at Columbia University and a medical director in the Laboratory of Personalized Genomic Medicine at Columbia Medical Center.  

He is an active member of the Association for Molecular Pathology (AMP) where he serves on the organization’s Strategy Committee and was the former vice chair for new codes and pricing on the Economic Affairs Committee. He is also a member of the Pathology Coding Caucus in the College of American Pathologists (CAP) and the Molecular Pathology Advisory Group in the American Medical Association (AMA).  

Dr. Sireci received a bachelor’s degree in chemistry from New York University, a medical degree from the Johns Hopkins University School of Medicine, and a master’s degree in Biostatistics from the Mailman School of Public Health at Columbia University. He completed his residency training in Clinical Pathology in the New York Presbyterian Hospital-Columbia, where he also served as chief resident.

View more blog posts by Nino.

Questions or need more information? Contact us at info@happylungsproject.org

Home Health Agencies and Services: Coordinated Cancer Care for Patients

Home health agencies offer a wide range of services designed to support cancer patients undergoing treatment, helping them manage both physical symptoms and emotional challenges.

These services include skilled nursing care, physical therapy, and occupational therapy – all delivered at home to enhance comfort and convenience. Home care aides assist with daily living activities, providing essential support under the supervision of healthcare professionals.

Home health care agencies and healthcare teams work together to provide comprehensive care, taking into account the patient’s specific needs and treatment plans. Home health care providers are trained to recognize common symptoms and side effects, ensuring timely medical intervention.

In addition to personal care, many agencies also supply medical equipment, essential supplies, and hospice care for patients with advanced cancer.

Nutrition and Meal Planning

Nutrition plays a critical role in cancer care. Keeping a well-balanced diet can help support the immune system, maintain energy levels, , and reduce treatment-related complications.

Home care services often include meal planning and preparation tailored to each patient’s dietary needs and preferences. For those unable to eat normally, tube feedings and other forms of nutritional support may be provided to ensure proper nourishment.

In addition to preparing meals, caregivers and home health professionals can educate patients on healthy eating habits, helping them make informed choices that benefit their overall health during treatment.

Emotional and Psychological Support

The emotional toll of a cancer diagnosis can be just as challenging as the physical symptoms. Emotional and psychological support is vital for helping patients process their experiences and maintain their mental well-being. Effective communication between caregivers, healthcare teams, and patients is essential for addressing both medical and emotional needs.

Home care services may offer access to counseling, support groups, and mental health resources specifically geared toward cancer patients. These services can provide a safe space for patients to express their feelings, reduce anxiety, and build resilience. These services provide support for daily activities and enhance the quality of life for patients.

Support doesn’t stop with the patient. Family members and caregivers can also benefit from emotional guidance, helping them avoid burnout and stay strong for their loved one. Compassionate care providers understand the importance of supporting the whole person, not just the disease.

Finding Home Health Care Services

For many families, hiring home care services can feel overwhelming. However, with the right information and resources, it’s possible to find the best possible care for a loved one battling cancer.

When choosing an agency, it’s important to evaluate factors like cost, services offered, and the agency’s reputation. While some families may consider hiring independent contractors for personalized care, it’s crucial to ensure that all caregivers are properly trained and certified.

Finding the right home health care provider can feel daunting, but a variety of resources are available to guide patients and families through the process. The American Cancer Society, social workers, and healthcare professionals can offer reliable recommendations and support. Home healthcare services provide essential medical and personal care tailored to the needs of cancer patients.

Families can explore options through home health agencies, personal care providers, and hospice care organizations, all of which offer specialized services tailored to the needs of cancer patients.

Online tools, such as the Medicare website, can help identify accredited providers in your area. Additionally, personal referrals from doctors or friends can lead to trusted and compassionate care solutions. In most cases, health insurance covers home health services, making it easier for families to access the care they need.

Paying for Home Health Care

Paying for home health care can be a significant concern for cancer patients and their families. Fortunately, there are several options available to help cover the costs. Medicare, Medicaid, and private insurance plans may cover some or all of the costs of home health care services, including intermittent skilled nursing care and hospice services. It’s important to understand your coverage and out of pocket costs.

Additionally, some states offer programs to help cover the costs of home health care for low-income individuals. It’s essential to work with a healthcare team and insurance provider to determine the best options for paying for home health care. In some cases, patients may need to self-pay for certain services, but this can be a worthwhile investment in their health and well-being.

Improving Your Quality of Life

Home health services are a vital component of cancer treatment and care, providing medical care and support to individuals in the comfort of their own homes. By working with home health agencies, personal care agencies, and healthcare teams, cancer patients can receive comprehensive care that addresses their physical, emotional, and social needs. While paying for home health care can be a concern, there are several options available to help cover the costs. By prioritizing home health care and coordinated care, cancer patients can improve their quality of life, manage their symptoms, and receive the best possible care.

Next Steps – Take Action

Find a home health care agency

Making decisions about cancer care

Apply for HealthWell Foundation Grant

CancerCare Financial Assistance Program

References

https://www.cancer.org/cancer/managing-cancer/finding-care/home-care-agencies.html

https://www.cancer.gov/about-cancer/advanced-cancer/care-choices